Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anita Swamy

Pediatric Endocrinology Chicago, IL Medical Doctor

NPI 1255546842 CMS profile 713075

6501 S Promontory Dr, Chicago, IL 60649

Open in the dashboard

General payments

$1,399,099

1,373 records reported · program years 2019–2025

Research payments

$375

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anita Swamy of Chicago, IL is reported in the CMS Open Payments database as having received $1,399,099 across 1,373 general payments and $375 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $258,267 302
2024 General $240,078 294
2023 General $276,658 225
2022 General $157,419 138
2021 General $127,451 113
2020 General $116,425 107
2020 Research $375 1
2019 General $222,800 194

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anita Swamy
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Anita Swamy were reported at $258,267. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Anita Swamy Pediatric Endocrinology median Middle half National median
2019 $222,800 $196 $68–$845 $163
2020 $116,425 $124 $37–$722 $114
2021 $127,451 $134 $35–$691 $132
2022 $157,419 $177 $47–$726 $149
2023 $276,658 $236 $75–$887 $160
2024 $240,078 $259 $91–$979 $164
2025 $258,267 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dexcom, Inc. $446,900 349 payments
  2. Novo Nordisk Inc $346,550 324 payments
  3. Insulet Corporation $339,370 468 payments
  4. Sanofi-Aventis U.S. LLC $259,715 214 payments
  5. Genzyme Corporation $4,497 3 payments
  6. Medtronic MiniMed, Inc. $1,657 4 payments
  7. Tandem Diabetes Care, Inc. $180 4 payments
  8. Abbott Laboratories $158 2 payments
  9. Xeris Pharmaceuticals, Inc. $20 1 payment
  10. Beta Bionics, Inc. $18 2 payments
  11. Other $34 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $643,119 258 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $371,789 158 payments
  3. Travel and Lodging $189,994 541 payments
  4. Consulting Fee $71,777 24 payments
  5. Honoraria $50,970 13 payments
  6. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $45,919 24 payments
  7. Food and Beverage $25,435 352 payments
  8. Education $97 3 payments
Products named General payments · program years 2019–2025
  1. Omnipod Insulin Pump $268,328 396 payments
  2. TZIELD $235,957 197 payments
  3. DEXCOM G7 GSS (161) $225,042 177 payments
  4. Ozempic $144,503 132 payments
  5. RYBELSUS $135,192 128 payments
  6. Dexcom G6 Transmitter Endocrinology $84,448 72 payments
  7. Omnipod Insulin Pump $71,042 72 payments
  8. DEXCOM STELO GLUCOSE BIOSENSOR $60,716 56 payments
  9. DEXCOM CGM $57,091 32 payments
  10. DEXCOM G6 TRANSMITTER Endocrinology $42,990 36 payments
  11. Other $81,166 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Roche Diabetes Care, Inc. $375 1 payment

Records

1,374 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record